|Name of listed company:||Chugai Pharmaceutical Co., Ltd.|
|Code number:||4519 (1st Section of Tokyo Stock Exchange)|
|Head office:||1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo|
|President & CEO:||Tatsuro Kosaka|
|Inquiries to:||Masahiko Uchida,|
|General Manager, Corporate Communications Dept.|
F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its half year results 2018 (January 1 – June 30, 2018).
Roche owns 59.89% of Chugai’s outstanding shares (61.27% of the total number of shares issued excluding treasury stock) as of end of June 2018.
Its press release and presentation materials can be found on its website (https://www.roche.com).
Chugai’s performance for the period of January 1 to June 30, 2018 is included in the announced Roche Group’s results.
|Media Releases||Investor Updates||Presentations||Half-Year Report 2018|